602 related articles for article (PubMed ID: 18036365)
1. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
Michos ED; Blumenthal RS
J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
[TBL] [Abstract][Full Text] [Related]
5. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
6. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
O'Keefe JH; Carter MD; Lavie CJ; Bell DS
Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
[TBL] [Abstract][Full Text] [Related]
7. The JUPITER trial: How will it change clinical practice?
Watson KE
Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
[TBL] [Abstract][Full Text] [Related]
8. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Ridker PM; MacFadyen J; Libby P; Glynn RJ
Am J Cardiol; 2010 Jul; 106(2):204-9. PubMed ID: 20599004
[TBL] [Abstract][Full Text] [Related]
9. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
Carter NJ
Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Fonseca FA; Izar MC
Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Everett BM; Glynn RJ; MacFadyen JG; Ridker PM
Circulation; 2010 Jan; 121(1):143-50. PubMed ID: 20026779
[TBL] [Abstract][Full Text] [Related]
12. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
Ridker PM;
Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996
[No Abstract] [Full Text] [Related]
13. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of statin therapy for vascular event prevention in adults with elevated C-reactive protein: implications of JUPITER.
Slejko JF; Page RL; Sullivan PW
Curr Med Res Opin; 2010 Oct; 26(10):2485-97. PubMed ID: 20828360
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein lowering with rosuvastatin in the METEOR study.
Peters SA; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Raichlen JS; Bots ML
J Intern Med; 2010 Aug; 268(2):155-61. PubMed ID: 20412373
[TBL] [Abstract][Full Text] [Related]
16. Another look at the results of the JUPITER trial.
Kappagoda CT; Amsterdam EA
Am J Cardiol; 2009 Dec; 104(11):1603-5. PubMed ID: 19932800
[TBL] [Abstract][Full Text] [Related]
17. The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?
Sgueglia GA; Crea F
J Cardiovasc Med (Hagerstown); 2011 Jan; 12(1):66-70. PubMed ID: 21139510
[TBL] [Abstract][Full Text] [Related]
18. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
Bays HE; Davidson M; Jones MR; Abby SL
Am J Cardiol; 2006 Apr; 97(8):1198-205. PubMed ID: 16616026
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
Burmeister JE; Miltersteiner DR; Campos BM
J Nephrol; 2009; 22(1):83-9. PubMed ID: 19229822
[TBL] [Abstract][Full Text] [Related]
20. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.
McMurray JJ; Kjekshus J; Gullestad L; Dunselman P; Hjalmarson A; Wedel H; Lindberg M; Waagstein F; Grande P; Hradec J; Kamenský G; Korewicki J; Kuusi T; Mach F; Ranjith N; Wikstrand J;
Circulation; 2009 Dec; 120(22):2188-96. PubMed ID: 19917888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
